IGC Pharma Inc
IGC0.296USD
-0.007-2.37%
Close 12/26, 16:00（ET）Quotes delayed by 15 min
27.22MMarket Cap
LossP/E TTM
More Details of IGC Pharma Inc Company
IGC Pharma, Inc. is a clinical-stage company, which is engaged in developing treatments for Alzheimer’s disease. The Company’s flagship drug, IGC-AD1, is an investigational drug tackles agitation, a major burden for patients and caregivers by addressing neuroinflammation. The Company operates through two segments: Life Sciences Segment and Infrastructure Segment. Its TGR-63 has demonstrated its potential to disrupt the progression of Alzheimer’s by targeting Aβ plaques, a key disease hallmark. The Company’s IGC-1C represents a potential breakthrough by targeting tau protein and neurofibrillary tangles, aiming to modify the disease course. Its IGC-M3 focuses on early intervention by inhibiting Aβ plaque formation, potentially slowing cognitive decline. Its LMP is designed to target multiple hallmarks of Alzheimer’s disease, including Aβ plaques and neurofibrillary tangles for a comprehensive therapeutic effect. It seeks to leverage artificial intelligence (AI) for Alzheimer's research.
IGC Pharma Inc Info
Ticker SymbolIGC
Company nameIGC Pharma Inc
IPO dateApr 13, 2006
CEOMukunda (Ram)
Number of employees70
Security typeOrdinary Share
Fiscal year-endApr 13
Address10224 Falls Road
CityPOTOMAC
Stock exchangeNASDAQ OMX – NASDAQ Basic Amex
CountryUnited States of America
Postal code20854
Phone13015294996
Websitehttps://igcpharma.com/
Ticker SymbolIGC
IPO dateApr 13, 2006
CEOMukunda (Ram)
Company Executives of IGC Pharma Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Ram Mukunda
Mr. Ram Mukunda
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
3.99M
-2.44%
Mr. Richard K. Prins
Mr. Richard K. Prins
Independent Chairman of the Board
Independent Chairman of the Board
1.27M
--
Ms. Claudia Grimaldi
Ms. Claudia Grimaldi
Vice-President, Principal Financial Officer, Chief Compliance Officer, Director
Vice-President, Principal Financial Officer, Chief Compliance Officer, Director
1.13M
-4.22%
Mr. Terry L. Lierman
Mr. Terry L. Lierman
Independent Director
Independent Director
29.41K
--
Congressma James (Jim) Moran
Congressma James (Jim) Moran
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Ram Mukunda
Mr. Ram Mukunda
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
3.99M
-2.44%
Mr. Richard K. Prins
Mr. Richard K. Prins
Independent Chairman of the Board
Independent Chairman of the Board
1.27M
--
Ms. Claudia Grimaldi
Ms. Claudia Grimaldi
Vice-President, Principal Financial Officer, Chief Compliance Officer, Director
Vice-President, Principal Financial Officer, Chief Compliance Officer, Director
1.13M
-4.22%
Mr. Terry L. Lierman
Mr. Terry L. Lierman
Independent Director
Independent Director
29.41K
--
Congressma James (Jim) Moran
Congressma James (Jim) Moran
Independent Director
Independent Director
--
--
Revenue Breakdown
Currency: USDUpdated: Mon, Oct 6
Currency: USDUpdated: Mon, Oct 6
FY2026Q1
FY2025
FY2025Q4
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2021
FY2020
Relevant data have not been disclosed by the company yet.
By RegionUSD
Name
Revenue
Proportion
U.S.
328.00K
100.00%
India
0.00
0.00%
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Thu, Dec 4
Updated: Thu, Dec 4
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Bradbury Asset Management (Hong Kong) Limited
14.89%
Mukunda (Ram)
4.30%
Prins (Richard K)
1.37%
Renaissance Technologies LLC
1.31%
The Vanguard Group, Inc.
1.24%
Other
76.90%
Shareholders
Shareholders
Proportion
Bradbury Asset Management (Hong Kong) Limited
14.89%
Mukunda (Ram)
4.30%
Prins (Richard K)
1.37%
Renaissance Technologies LLC
1.31%
The Vanguard Group, Inc.
1.24%
Other
76.90%
Shareholder Types
Shareholders
Proportion
Investment Advisor
17.15%
Individual Investor
8.11%
Hedge Fund
2.07%
Investment Advisor/Hedge Fund
1.27%
Research Firm
0.18%
Bank and Trust
0.04%
Venture Capital
0.04%
Other
71.15%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
47
17.39M
18.91%
+329.46K
2025Q2
48
24.37M
29.05%
+763.42K
2025Q1
48
23.10M
27.53%
-54.32K
2024Q4
50
22.65M
28.43%
-577.77K
2024Q3
50
22.62M
28.57%
-499.00K
2024Q2
53
22.57M
32.34%
+1.13M
2024Q1
57
29.78M
44.76%
+8.32M
2023Q4
56
19.20M
35.05%
+5.05M
2023Q3
55
19.57M
35.63%
+5.55M
2023Q2
57
16.90M
31.85%
+2.68M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Bradbury Asset Management (Hong Kong) Limited
13.82M
15.03%
--
--
Aug 15, 2025
Mukunda (Ram)
4.09M
4.45%
--
--
Aug 15, 2025
Prins (Richard K)
1.27M
1.38%
--
--
Aug 15, 2025
Renaissance Technologies LLC
55.02K
0.06%
+55.02K
--
Jun 30, 2025
The Vanguard Group, Inc.
645.17K
0.7%
--
--
Jun 30, 2025
Grimaldi (Claudia)
1.18M
1.29%
--
--
Aug 15, 2025
Moran (James P)
1.11M
1.2%
--
--
Aug 15, 2025
Geode Capital Management, L.L.C.
703.30K
0.76%
+3.29K
+0.47%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
703.80K
0.77%
--
--
Jun 30, 2025
Citadel Advisors LLC
270.97K
0.29%
+176.50K
+186.82%
Jun 30, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of IGC Pharma Inc?
The top five shareholders of IGC Pharma Inc are:
Bradbury Asset Management (Hong Kong) Limited holds 13.82M shares, accounting for 15.03% of the total shares.
Mukunda (Ram) holds 4.09M shares, accounting for 4.45% of the total shares.
Prins (Richard K) holds 1.27M shares, accounting for 1.38% of the total shares.
Renaissance Technologies LLC holds 55.02K shares, accounting for 0.06% of the total shares.
The Vanguard Group, Inc. holds 645.17K shares, accounting for 0.70% of the total shares.
Bradbury Asset Management (Hong Kong) Limited holds 13.82M shares, accounting for 15.03% of the total shares.
Mukunda (Ram) holds 4.09M shares, accounting for 4.45% of the total shares.
Prins (Richard K) holds 1.27M shares, accounting for 1.38% of the total shares.
Renaissance Technologies LLC holds 55.02K shares, accounting for 0.06% of the total shares.
The Vanguard Group, Inc. holds 645.17K shares, accounting for 0.70% of the total shares.
What are the top three shareholder types of IGC Pharma Inc?
The top three shareholder types of IGC Pharma Inc are:
Bradbury Asset Management (Hong Kong) Limited
Mukunda (Ram)
Prins (Richard K)
Bradbury Asset Management (Hong Kong) Limited
Mukunda (Ram)
Prins (Richard K)
How many institutions hold shares of IGC Pharma Inc (IGC)?
As of 2025Q3, 47 institutions hold shares of IGC Pharma Inc, with a combined market value of approximately 17.39M, accounting for 18.91% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -10.14%.
What is the biggest source of revenue for IGC Pharma Inc?
In FY2026Q1, the -- business generated the highest revenue for IGC Pharma Inc, amounting to -- and accounting for --% of total revenue.
